William Blair Issues Pessimistic Outlook for RARE Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at William Blair reduced their Q4 2026 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a report issued on Monday, July 14th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will earn $0.99 per share for the quarter, down from their prior forecast of $1.09. William Blair has a "Outperform" rating and a $65.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share.

Several other equities research analysts also recently issued reports on RARE. JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Wells Fargo & Company dropped their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. Guggenheim reiterated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Morgan Stanley dropped their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday. Finally, Wedbush dropped their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average price target of $83.64.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE traded up $0.10 during trading on Tuesday, hitting $27.41. The company's stock had a trading volume of 2,147,403 shares, compared to its average volume of 961,710. The company has a market capitalization of $2.59 billion, a PE ratio of -4.66 and a beta of 0.26. Ultragenyx Pharmaceutical has a fifty-two week low of $26.85 and a fifty-two week high of $60.37. The stock's 50-day moving average price is $36.00 and its two-hundred day moving average price is $38.46.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The firm had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. During the same period in the previous year, the business posted ($2.03) earnings per share. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.0% on a year-over-year basis.

Insider Buying and Selling

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director directly owned 15,344 shares of the company's stock, valued at approximately $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 3,167 shares of company stock worth $118,824 over the last quarter. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System boosted its stake in Ultragenyx Pharmaceutical by 0.3% during the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock worth $3,284,000 after acquiring an additional 268 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 323 shares in the last quarter. Xponance Inc. boosted its holdings in Ultragenyx Pharmaceutical by 2.8% in the first quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock worth $455,000 after acquiring an additional 347 shares in the last quarter. BOKF NA grew its stake in shares of Ultragenyx Pharmaceutical by 5.0% in the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after acquiring an additional 382 shares during the last quarter. Finally, Oak Ridge Investments LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 2.3% during the first quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock valued at $643,000 after acquiring an additional 395 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.